Jay Mei

2.0k total citations
47 papers, 808 citations indexed

About

Jay Mei is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Jay Mei has authored 47 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 17 papers in Molecular Biology and 13 papers in Hematology. Recurrent topics in Jay Mei's work include Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Jay Mei is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Jay Mei collaborates with scholars based in United States, China and Germany. Jay Mei's co-authors include James M. Phang, Steven P. Donald, Jian Yu, David Valle, Norman G. Hord, Dolores Winterstein, Antonio Palumbo, Sui‐Po Zhang, Meletios Α. Dimopoulos and Christopher M. Flores and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jay Mei

43 papers receiving 782 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay Mei United States	13	451	236	204	139	110	47	808
Lora B. Kramer United States	22	871 1.9×	298 1.3×	230 1.1×	87 0.6×	98 0.9×	34	1.2k
Giovanni Di Maira Italy	19	1.0k 2.3×	310 1.3×	109 0.5×	119 0.9×	136 1.2×	41	1.6k
Wenqing Qi United States	20	668 1.5×	370 1.6×	43 0.2×	83 0.6×	85 0.8×	42	1.0k
Xianping Shi China	20	683 1.5×	261 1.1×	154 0.8×	148 1.1×	80 0.7×	35	1.0k
David W. End United States	15	631 1.4×	301 1.3×	301 1.5×	76 0.5×	131 1.2×	26	1.1k
Micheline J. Moussalli United States	20	646 1.4×	174 0.7×	442 2.2×	233 1.7×	108 1.0×	23	1.4k
María José Muñoz-Alonso Spain	15	604 1.3×	262 1.1×	75 0.4×	113 0.8×	39 0.4×	22	840
Daniel Iglesias‐Serret Spain	20	741 1.6×	306 1.3×	76 0.4×	133 1.0×	186 1.7×	32	1.0k
Laura Engstrom United States	9	557 1.2×	260 1.1×	340 1.7×	158 1.1×	64 0.6×	12	1.3k
Naiara Santana-Codina United States	11	659 1.5×	169 0.7×	123 0.6×	403 2.9×	76 0.7×	14	1.1k

Countries citing papers authored by Jay Mei

Since Specialization

Citations

This map shows the geographic impact of Jay Mei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Mei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Mei more than expected).

Fields of papers citing papers by Jay Mei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Mei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Mei. The network helps show where Jay Mei may publish in the future.

Co-authorship network of co-authors of Jay Mei

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Mei. A scholar is included among the top collaborators of Jay Mei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Mei. Jay Mei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Huajing, Tengteng Li, Bohua Li, et al.. (2024). ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation. Cancer Research. 84(10). 1680–1698. 11 indexed citations

Piha‐Paul, Sarina A., Shivani Singh, Jing Peng, et al.. (2024). A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM).. Journal of Clinical Oncology. 42(16_suppl). TPS2691–TPS2691. 4 indexed citations

Li, Li, Yan Ma, Xiaobo Wang, et al.. (2023). Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience. Blood. 142(Supplement 1). 6301–6301.

Chen, Peng, et al.. (2023). 1391 Antibody targeting a specific epitope of LILRB4 induces potent ADCC/ADCP effect against leukemia cells. SHILAP Revista de lepidopterología. A1546–A1546. 1 indexed citations

Tong, Xiwen, Shuai Su, Bin Xu, et al.. (2023). Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment. Blood. 142(Supplement 1). 5837–5837.

Hua, Jiahui, et al.. (2022). Abstract 2576: ATG-037, a highly potent small molecule CD73 inhibitor has superior activity of reversing immunosuppression in higher-AMP environments compared with anti-CD73 antibodies. Cancer Research. 82(12_Supplement). 2576–2576. 3 indexed citations

Wendtner, Clemens‐Martin, Michael Hallek, Graeme Fraser, et al.. (2016). Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leukemia & lymphoma. 57(6). 1291–1299. 15 indexed citations

Du, Xin, Jie Jin, Zhen Cai, et al.. (2016). Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. BMC Cancer. 16(1). 46–46. 1 indexed citations

Bühler, Andreas, Thomas J. Kipps, Laura Z. Rassenti, et al.. (2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal. 6(3). e404–e404. 11 indexed citations

10.

Yu, Li, Xin Du, Jie Jin, et al.. (2015). Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. International Journal of Hematology. 101(6). 569–577. 7 indexed citations

11.

Gao, Yue, Bin Fan, Kha Le, et al.. (2015). Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial. Blood. 126(23). 2509–2509. 5 indexed citations

12.

Brown, Jennifer R., Wael A. Harb, Brian T. Hill, et al.. (2013). Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 122(21). 1630–1630. 39 indexed citations

13.

Dimopoulos, Meletios Α., Antonio Palumbo, Roman Hájek, et al.. (2013). Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leukemia & lymphoma. 55(7). 1489–1497. 28 indexed citations

14.

Palumbo, Antonio, Meletios Α. Dimopoulos, Michel Delforge, et al.. (2009). A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.. Blood. 114(22). 613–613. 30 indexed citations

15.

Yan, Zhengyin, Gary W. Caldwell, Donald R. Gauthier, et al.. (2006). N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES. Drug Metabolism and Disposition. 34(5). 748–755. 27 indexed citations

16.

Qin, Na, et al.. (2005). Cloning, Expression, and Functional Characterization of Human Cyclooxygenase-1 Splicing Variants: Evidence for Intron 1 Retention. Journal of Pharmacology and Experimental Therapeutics. 315(3). 1298–1305. 60 indexed citations

17.

Mei, Jay, et al.. (2004). Multiplexed RT- PCR for High Throughput Screening Applications. Combinatorial Chemistry & High Throughput Screening. 7(8). 727–732. 8 indexed citations

18.

Pinhasov, Albert, Jay Mei, Dhammika Amaratunga, et al.. (2004). Gene Expression Analysis for High Throughput Screening Applications. Combinatorial Chemistry & High Throughput Screening. 7(2). 133–140. 10 indexed citations

19.

Mei, Jay. (2002). Matrix metalloproteinase(s) mediate(s) NO-induced dissociation of beta-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex. Carcinogenesis. 23(12). 2119–2122. 50 indexed citations

20.

Mei, Jay, Norman G. Hord, Dolores Winterstein, Steven P. Donald, & James M. Phang. (1999). Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated β-catenin–LEF-1 transcription complex in mouse colonic epithelial cells contrasting in Apc. Carcinogenesis. 20(4). 737–740. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact